Financial Statement 16/17
September 2016 – August 2017, Diamyd Medical AB (publ), Fiscal year 2016/2017The period September 1, 2016 – August 31, 2017 in brief · R&D-expenses amounted to MSEK -12.9 (-6.2) of which the fourth quarter constituted MSEK -3.1 (-1.9) · Net result amounted to MSEK -25.6 (-32.0) of which the fourth quarter amounted to MSEK -6.5 (-4.8). Previous year’s result was charged with an impairment in associated company of MSEK -13.5 · Result per share, before and after dilution, amounted to SEK -0.7 (-1.3) of which the fourth quarter constituted SEK -0.1 (-0.2) · Cash flow from